ArticleTherapeutic advances in endocrinology and metabolism2017
Dual control of pituitary thyroid stimulating hormone secretion by thyroxine and triiodothyronine in athyreotic patients.
Article in Therapeutic advances in endocrinology and metabolism, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06083636 (Improvement of Laboratory Diagnostics in Hypothyroid Patients Using Levothyroxine), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Improvement of Laboratory Diagnostics in Hypothyroid Patients Using Levothyroxine
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- Metabolic and hepatic differences among biochemically euthyroid individuals with distinct thyroid hormone sources: a comparative study.BMC endocrine disorders · 2026Article
- Association Between FT4/FT3 Ratio and Short-Term Treatment Response in Differentiated Thyroid Cancer Patients.International journal of endocrinology · 2025Article
- The role of supporting and disruptive mechanisms of FT3 homeostasis in regulating the hypothalamic-pituitary-thyroid axis.Therapeutic advances in endocrinology and metabolism · 2023Article
- Free triiodothyronine/free thyroxine ratio in children with congenital hypothyroidism.Endocrine connections · 2022Article
- Minor perturbations of thyroid homeostasis and major cardiovascular endpoints-Physiological mechanisms and clinical evidence.Frontiers in cardiovascular medicine · 2022Review
- Functional and Symptomatic Individuality in the Response to Levothyroxine Treatment.Frontiers in endocrinology · 2019Article
- Mathematical Modeling of the Pituitary-Thyroid Feedback Loop: Role of a TSH-TFrontiers in endocrinology · 2018Article
- Recent Advances in Thyroid Hormone Regulation: Toward a New Paradigm for Optimal Diagnosis and Treatment.Frontiers in endocrinology · 2017Review
- Advances in applied homeostatic modelling of the relationship between thyrotropin and free thyroxine.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatient responses to levothyroxine (LT4) monotherapy vary considerably. We sought to differentiate contributions of FT4 and FT3 in controlling pituitary thyroid stimulating hormone (TSH) secretion.
methodsWe retrospectively assessed the relationships between TSH and thyroid hormones in 319 patients with thyroid carcinoma through 2914 visits on various LT4 doses during follow-up for 5.5 years (median, IQR 4.2, 6.9). We also associated patient complaints with the relationships.
resultsUnder varying dose requirements (median 1.84 µg/kg, IQR 1.62, 2.11), patients reached TSH targets below 0.4, 0.1 or 0.01 mIU/l at 73%, 54% and 27% of visits. While intercept, slope and fit of linearity of the relationships between lnTSH and FT4/FT3 varied between individuals, gender, age, LT4 dose and deiodinase activity influenced the relationships in the cohort (all
conclusionsVariation in deiodinase activity and resulting FT3 levels shape the TSH-FT4 relationship in LT4-treated athyreotic patients, suggesting cascade control of pituitary TSH production by the two hormones. Consequently, measurement of FT3 and calculation of conversion efficiency may identify patients with impaired biochemistry and a resulting lack of symptomatic control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.